6 January 2026 in Journal of the American Heart Association
Background: Given an epidemiological association between hypertension and osteoarthritis, we aim to elucidate how vascular pathology triggers avascular articular cartilage loss by comparing vascular and joint phenotypes between spontaneously hypertensive rats and normotensive Wistar Kyoto rats at tissue, cellular, and molecular levels. Methods: Systemic and local endothelial function were assessed via blood pressure monitoring and photoacoustic imaging of knee joints, respectively (n=5–6). Tissue and cellular damages in articular cartilage, subchondral bone, and synovium were systemically evaluated by radiological and histological examination (n=6). Endothelial transcriptional changes were delineated via bulk RNA‐seq (n=3). The secretome of human endothelial cells under oxidative stress was analyzed via proteomics to identify key factors in chondrocyte senescence (n=4). Captopril, an antihypertensive medication, was adopted as a tool to rescue chondrocyte senescence and osteoarthritis both in vitro (n=3) and in vivo (n=6). Results: Compared with Wistar Kyoto rats, spontaneously hypertensive rats exhibited higher blood pressure and local joint hypoxia with increased endothelial oxidative stress as early as 3 months old. Notably, these endothelial dysfunctions preceded the onset of structural joint damage. By 9 months of age, spontaneously hypertensive rats developed osteoarthritis‐like pathology characterized by senescent chondrocyte accumulation and cartilage degradation, which could be mitigated by captopril. Transcriptomic and proteomic analyses of rat and human endothelial cells revealed upregulated IGFBPs (insulin‐like growth factor‐binding proteins). Among them, IGFBP6 was identified to induce chondrocyte senescence in vitro. This effect can be modified by captopril treatment. Conclusions: Systemic vascular dysfunction may induce local joint damage with upregulation of endothelial IGFBPs secretion such as IGFBP6. This study highlights a potential therapeutic target for preventing joint structural damage by addressing endothelial dysfunction.
29 October 2026 in Hypertension
BACKGROUND: Systemic hypertension is a risk factor for glaucoma, a leading cause of irreversible blindness, yet the mechanistic basis connecting the 2 conditions remains elusive. METHODS: A longitudinal assessment of blood pressure, intraocular pressure, retinal function, structure, and perfusion was conducted in spontaneously hypertensive rats and Wistar-Kyoto rats. Transcriptomic analyses and immunofluorescence staining were performed to investigate hypertension-associated retinal biochemical changes. AAV-mediated knockdown of endothelin 2 was used to investigate its mechanistic role. RESULTS: Hypertensive rats develop accelerated retinal degeneration marked by retinal thinning, functional impairment, reduced perfusion, and progressive neuroinflammation. Critically, these changes occur despite persistently low intraocular pressure, indicating an intraocular pressure-independent mechanism underlying the pathology. Biochemical analyses identified robust activation of the retinal endothelin system, with endothelin 2 the most significantly upregulated component. AAV-mediated retinal endothelin 2 knockdown substantially restored retinal function, ameliorated neuroinflammation, and enhanced retinal blood flow in hypertensive rats. Pharmacological blockade of endothelin receptor type A, but not type B, replicated these protective effects without altering intraocular pressure. CONCLUSIONS: Our findings establish endothelin 2 as an important, intraocular pressure-independent contributing factor to hypertension-associated retinal neurodegeneration and identify the endothelin-endothelin receptor type A axis as a potential therapeutic target to prevent vision loss in patients with hypertension.
19 December 2025 in Journal of Orthopaedic Translation
Current methods to assess growth plate predominantly rely on rudimentary metrics such as tissue thickness, which fail to capture the dynamic, spatial and functional heterogeneity of chondrocyte populations during endochondral ossification. To address this gap, we developed a computational histomorphometric pipeline (Growth Plate Professional Analyzer, “GP Pro”), designed to quantify chondrocyte kinetics and maturation gradients at single-cell resolution using routine histological tissue sections. GP Pro integrates three automated modules: (1) batch processing of whole-slide images (WSIs) with growth plate localization, (2) segmentation of the growth plate using Segment Anything Model 2 (SAM2), and (3) single-cell lacunae analysis to extract morphometric and spatial distribution features across differentiation stages. For GP PRO's feasibility study, we conducted high-throughput testing on mouse/hamster/rat knee sections stained with Safranin-O/fastgreen (Safranin-O) and Hematoxylin & Eosin (H&E) to evaluate the computational efficiency and accuracy of the whole system and built-in functions. For GP PRO's application validation, tibial growth plates from normotensive Wistar-Kyoto (WKY) and spontaneously hypertensive rats (SHRs) were tested by the pipeline, correlating outputs with histochemical staining and micro-CT scanning results. GP PRO demonstrates satisfactory computational efficiency, with a processing time as low as 3.6 s per section and achieves an end-to-end automated processing success rate of above 95 %. Additionally, it boasts an average chondrocyte identification accuracy of 90.28 % and a macro-precision of 94.76 % in cell classification. In the application of SHR, GP Pro revealed a 4.03 percentage points increase in proliferative chondrocyte proportion (p < 0.05; 95 % CI: 0.59–7.47) and the presence of aberrantly elongated pre-hypertrophic chondrocytes at 3-month-old, indicative of maturation arrest. These cellular perturbations aligned with micro-CT showing a 36.04 percentage points decrease in primary spongiosa bone volume fraction (p < 0.001; 95 % CI: 30.10–41.97), suggesting compromised osteogenic coupling. Histology confirmed premature hyperproliferation and delayed hypertrophic differentiation in SHR growth plates. GP Pro establishes a scalable platform for mapping chondrocyte behavior in situ, enabling unprecedented resolution of growth plate pathobiology. By linking hypertrophic differentiation delays to trabecular bone deficits in hypertension, this tool advances mechanistic studies of endochondral ossification and offers translational potential for diagnosing growth disorders or monitoring therapeutic interventions in multiple species. This study introduces GP Pro, an AI-driven histomorphometric platform that bridges pre-clinical research and clinical applications by enabling high-throughput, single-cell resolution analysis of growth plate dynamics directly from WSIs.